Michael Lahn
Company: iOnctura
Job title: Chief Medical Officer
Seminars:
Safety Observations from Small Molecule Inhibitors of ALK5 in Patients 1:00 pm
• How to overcome the non-clinical toxicity in animals • PK/PD modelling and the subsequent validation in patients • Safety monitoring in the clinicRead more
day: Track B - Day 2 PM
Roundtable Discussion 10:20 am
Having had an update on both TGF-β biology and the history of this target in oncology, you now have an opportunity to ask questions, share with and learn from your peersRead more
day: TGF-β Boot Camp Day
History of TGF-β in Oncology – Lessons from Small Molecule Inhibitors of ALK5 9:40 am
The field examining TGF-β is not new, but we are only just starting to see progress in the clinic. As this space grows and evolves, it is crucial to look back at what we know about TGF-β in oncology, how it has been targeted before, where the success has been seen and why setbacks occurred…Read more
day: TGF-β Boot Camp Day